Garten R J, Lai S, Zhang J, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China[J]. Int J Epidemiol, 2004, 33(1): 182-188. [2]Mao Q, Ray S C, Laeyendecker O, et al. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies[J]. J Virol, 2001, 75(7): 3259-3267. [3]Netski D M, Mao Q, Ray S C, et al. Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression[J]. J Acquir Immune Defic Syndr, 2008, 49(2): 136-141. [4]Fromentin R, Tardif M R, Tremblay M J. Inefficient fusion due to a lack of attachment receptor/co-receptor restricts productive human immunodeficiency virus type 1 infection in human hepatoma Huh7.5 cells[J]. J Gen Virol, 2011, 92(Pt 3): 587-597. [5]Upadya M H, Aweya J J, Tan Y J. Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases[J]. World J Gastroenterol, 2014, 20(11): 2913-2926. [6]Ariumi Y. Multiple functions of DDX3 RNA helicase in gene regulation, tumorigenesis, and viral infection[J]. Front Genet, 2014, 5: 423. [7]Yedavalli V S, Neuveut C, Chi Y H, et al. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function [J]. Cell, 2004, 119(3): 381-392. [8]Lin W, Weinberg E M, Tai A W, et al. HIV increases HCV replication in a TGF-beta1-dependent manner[J]. Gastroenterology, 2008, 134(3): 803-811. [9]Xiao P, Usami O, Suzuki Y, et al. Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4[J]. AIDS, 2008, 22(14): 1749-1757. [10]Pineda J A, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis [J]. Hepatology, 2005, 41(4): 779-789. [11]Koziel M J, Peters M G. Viral hepatitis in HIV infection [J]. N Engl J Med, 2007, 356(14): 1445-1454. [12]Kim A Y, Schulze-zur-Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection[J]. PLoS Med, 2006, 3(12): e492. [13] Data Collection on Adverse Events of Anti-HIV drugs (D: A: D) Study Group, Smith C, Sabin C A, et al. Factors associated with specific causes of death amongst HIV-positive individuals in The D: A: D？ Study[J]. AIDS, 2010, 24(10): 1537-1548. [14]Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection[J]. Lancet, 2003, 362(9397): 1708-1713. [15]Barcaui H S, Tavares G C, May S B, et al. Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil[J]. PLoS One, 2013, 8(7): e67734. [16]Pollard V W, Malim M H. The HIV-1 Rev protein[J]. Annu Rev Microiol, 1998, 52: 491-532. [17]Chao C H, Chen C M, Cheng P L, et al. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor[J]. Cancer Res, 2006, 66(13): 6579-6588. [18]Shih J W, Tsai T Y, Chao C H, et al. Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein[J]. Oncogene, 2008, 27(5): 700-714. [19]Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule[J]. Neuron, 2004, 43(4): 513-525. [20]Lai M C, Wang S W, Cheng L, et al. Human DDX3 interacts with the HIV-1 Tat protein to facilitate viral mRNA translation[J]. PLoS One, 2013, 8(7): e68665. [21]Yedavalli V S, Neuveut C, Chi Y H, et al. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function [J].Cell, 2004, 119(3): 381-392.
